{
    "nctId": "NCT00003140",
    "briefTitle": "Letrozole After Tamoxifen in Treating Women With Breast Cancer",
    "officialTitle": "A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5187,
    "primaryOutcomeMeasure": "Disease-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed primary invasive breast carcinoma resected at time of original diagnosis\n\n  * No ductal carcinoma in situ\n* Axillary lymph node negative, positive, or unknown\n* No evidence of metastases\n* No localized or distant breast cancer recurrence\n* Not registered on protocol NCCTG-893052, any other IBCSG protocol, or protocol SWOG-S9623\n* Hormone receptor status:\n\n  * Estrogen or progesterone receptor positive as defined by tumor receptor content at least 10 fmol/mg protein or receptor positive by ERICA or PgRICA\n  * Unknown status allowed if effort to determine status has been made by immunocytochemistry\n* No contralateral breast cancer\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Postmenopausal\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Postmenopausal defined by one of the following:\n\n  * Age 50 or over at start of adjuvant tamoxifen\n  * Under age 50 and considered postmenopausal by treating physician at start of adjuvant tamoxifen\n  * Under age 50 at start of adjuvant tamoxifen and had bilateral oophorectomy (surgical or radiation)\n  * Under age 50 and premenopausal at start of adjuvant tamoxifen, but became amenorrheic during tamoxifen and remained amenorrheic for at least 1 year\n  * Considered postmenopausal by physician with LH/FSH levels under the treatment center's postmenopausal limits\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 5 years\n\nHematopoietic:\n\n* WBC \u2265 3,000/mm\\^3 OR\n* Granulocyte count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic:\n\n* AST and/or ALT \\< 2 times upper limit of normal (ULN) (unless imaging examinations have ruled out metastatic disease)\n* Alkaline phosphatase \\< 2 times ULN (unless imaging examinations have ruled out metastatic disease)\n\nRenal:\n\n* Not specified\n\nOther:\n\n* No concurrent medical or psychiatric condition that would preclude study participation\n* No other malignancy within the past 5 years except adequately treated superficial squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n* Able to swallow study drug\n* Adequate oral intake\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Prior adjuvant chemotherapy allowed\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* Completed at least 4.5 but no more than 6 years of adjuvant tamoxifen after resection\n* Completed at least 4.5-6 years of adjuvant aromatase inhibitor as initial therapy or after tamoxifen\n* No more than 3 months since prior adjuvant tamoxifen\n* No concurrent hormone replacement therapy (e.g., megestrol)\n* No concurrent selective estrogen-receptor modulators (e.g., raloxifene or idoxifene)\n* Concurrent intermittent vaginal estrogens (e.g., Estring) allowed if other local measures for intractable vaginal atrophy are insufficient\n* No other concurrent aromatase inhibitors\n* No more than 2 years since prior aromatase inhibitor therapy (re-randomization)\n\nRadiotherapy:\n\n* Prior radiotherapy allowed\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* At least 1 month since prior investigational drugs\n* Prior treatment on a clinical trial for breast cancer allowed if permission has been obtained from the sponsors of the original study for their patient to participate on MA.17/JMA.17/BIG-97-01\n* No prior placebo on core protocol\n* No concurrent anticancer therapy\n* Concurrent thyroid medication, calcium, vitamin D, and bisphosphonates allowed",
    "sex": "FEMALE",
    "minimumAge": "0 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}